Brief: Silo Pharma Enters Into Exclusive License Agreement For Intranasal Technology Used In Spc-15 Treatment For PTSD
21/11/2023 13:04
Nov 21 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH
MEDSPRAY PHARMA BV FOR INTRANASAL TECHNOLOGY USED IN SPC-15
TREATMENT FOR PTSD
Source text for Eikon: ID:nGNX55xQc8
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement